0001567264 false 0001567264 2023-09-05 2023-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares










Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): September 5, 2023


Intensity Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware   001-41109   46-1488089

(State or Other Jurisdiction

of Incorporation) 

  (Commission File Number)   

(IRS Employer

Identification No.) 


1 Enterprise Drive, Suite 430

Shelton, CT

(Address of Principal Executive Offices)   (Zip Code)


(203) 221-7381 

(Registrant’s Telephone Number, Including Area Code)


Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class:   Trading Symbol(s):   Name of Exchange on Which Registered:
Common Stock, $0.0001 par value per share   INTS   The NASDAQ Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 







Item 7.01 Regulation FD Disclosure.


On September 5, 2023, Intensity Therapeutics, Inc. (the “Company”) announced via press release that it will present a corporate presentation at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K. A copy of the corporate presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K. 


The information contained in Item 7.01 in this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto are intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.   Description
99.1   Press Release, dated September 5, 2023.
99.2   Corporate Presentation of Intensity Therapeutics, Inc., dated September 11, 2023.
104   Cover Page Interactive Data File (formatted in Inline XBRL).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: September 5, 2023


  Intensity Therapeutics, Inc.
  By: /s/ Lewis H. Bender
    Name:  Lewis H. Bender
    Title: Chief Executive Officer


[Signature Page to the Form 8-K]